Showing results (41-50 of 223) with videos related to
Sort By:
Pageof 23
Pediatric Blood & Cancer|June 13, 2024
Population modeling analyses of crizotinib in pediatric patients with ALK-positive advanced cancersLi Jerry, Lin Swan, Nickens Dana, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2021
Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912)Jennifer H Foster, Stephan D Voss, David C Hall, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2010
A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumorsElizabeth Fox, Richard Aplenc, Rochelle Bagatell, et al.Current Opinion in Pediatrics|November 28, 2017
Evolving paradigms for new agent development in pediatric oncologyAndrea Flynn, Elizabeth FoxPain|September 1, 1987
Cerebrospinal fluid and plasma pharmacokinetics of morphine infusions in pediatric cancer patients and rhesus monkeysRaymond F Greene, Angela W Miser, Cindy M Lester, et al.Biochemistry|July 21, 2009
Conformational heterogeneity and quasi-static self-quenching in DNA containing a fluorescent guanine analogue, 3MI or 6MIKristi Wojtuszewski Poulin, Aleksandr V Smirnov, Mary E Hawkins, et al.Expert Review of Anticancer Therapy|April 13, 2007
Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitorElizabeth Fox, Susan E BatesThe Laryngoscope|December 21, 2016
Bevacizumab chemotherapy for management of pulmonary and laryngotracheal papillomatosis in a childKaren B Zur, Elizabeth FoxPediatric Blood & Cancer|December 19, 2013
Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT-751: a report from the Children's Oncology Group (ANBL0621)Elizabeth Fox, Yael P Mosse', Holly M Meany, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 18, 2006
A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumorsElizabeth Fox, John M Maris, Brigitte C Widemann, et al.Pageof 23